FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Wolff Stefani (Last) (First) (Middle) C/O NURIX THERAPEUTICS, INC. 1700 OWENS STREET, SUITE 205					Suer Name and Ticker or Trading Symbol Nurix Therapeutics, Inc. [NRIX] 3. Date of Earliest Transaction (Month/Day/Year) 01/19/2022					(Ch	eck all applic Directo	cable) or (give title	below)	wner (specify	
(Street) SAN FRANCE	isco C.	A	94158 (Zip)	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	Individual or Joint/Group Filing (Check Applicable ne) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				ınsactio	ction 2A. Deemed Execution Date,		3. Transacti Code (Ins	4. Secur Dispose tr. 5)	rities Acquired (A) o		5. Amount of Securities For Beneficially (D)		. Ownership orm: Direct D) or Indirect I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
1. Title of Derivative Conversion Security or Exercise (Month/Day/Year) 3. Transaction Date Execution Date Execution Date Tif any			4. Trans	uts, calls, warrants 5. Number of of Derivative			uired, Disposed of, or Benefic s, options, convertible securiti 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and An of Securities Underlying Derivative Sec (Instr. 3 and 4)		d Amount ies	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(,		
Employee Stock Option (right to buy)	\$19.49	01/19/2022		A		34,631		(1)	01/18/2032	Common Stock	34,631	\$0.00	34,631	D	
Restricted Stock Units	\$0.00 ⁽²⁾	01/19/2022		A		15,392		(3)	(4)	Common Stock	15,392	\$0.00	15,392	D	

Explanation of Responses:

- 1. The stock option vests as to 1/48 of the total shares monthly beginning February 19, 2022 until the option is fully vested on January 19, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- 2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
- 3. The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.
- 4. RSUs do not expire; they either vest or are canceled prior to the vest date.

Remarks:

/s/ Christine Ring, as Attorney-01/21/2022 in-Fact for Stefani Wolff

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.